Table 3.
Factors associated with NRM in current sample and subsamples: Univariate analysis
| Variable | Whole sample | Standardized difference (%) / original report | Whole sample N=286 | Adults, no FD, no drepanocytosis, no thalassemia N=223 | ||
|---|---|---|---|---|---|---|
| no (%) | HR (95%CI) | P-value | HR (95%CI) | P-value | ||
| Age | ||||||
| < 15 | 57 (20) | 1 | NA | |||
| 15–25 | 56 (20) | 0.58 (0.21 – 1.55) | 0.27 | 1 | ||
| 25–40 | 67 (23) | 0.71 (0.30 – 1.67) | 0.43 | 1.00 (0.36 – 2.82) | 0.99 | |
| 40–50 | 49 (17) | 1.34 (0.60 – 2.99) | 0.47 | 2.16 (0.82 – 5.67) | 0.12 | |
| ≥ 50 | 57 (20) | 1.21 (0.54 – 2.70) | 0.64 | 1.90 (0.72 – 5.00) | 0.19 | |
| Age < 15 or ≥ 40 | 163 (57) | 1.80 (1.00 – 3.24 | 0.049 | 2.01 (1.07 – 3.80) | 0.031 | |
| Female gender | 117 (41) | 0.96 (0.55 – 1.66) | 0.88 | 0.82 (0.43 – 1.56) | 0.54 | |
| Malignant disease | 251 (88) | 2.83 (0.88 – 9.08) | 0.080 | 0.98 (0.24 – 4.05) | 0.97 | |
| Cell source | ||||||
| BM | 123 (43) | 1 | 1 | |||
| PBSC | 124 (43) | 1.08 (0.58 – 1.99) | 0.81 | 0.95 (0.50 – 1.83) | 0.89 | |
| CB | 39 (14) | 2.55 (1.24 – 5.22) | 0.011 | 1.96 (0.65 – 5.89) | 0.23 | |
| Donor type | ||||||
| Matched related | 149 (52) | 1 | ||||
| Matched unrelated | 63 (22) | 1.76 (0.85 – 3.62) | 0.13 | 1.42 (0.66 – 3.03) | 0.37 | |
| Other | 74 (26) | 3.00 (1.62 – 5.55) | 0.0005 | 2.05 (0.99 – 4.22) | 0.052 | |
| Female donor to male recipient | 79 (28) | 0.74 (0.39 – 1.40) | 0.35 | 0.91 (0.46 – 1.82) | 0.79 | |
| Nonmyeloablative conditioning regimen | 116 (41) | 1.45 (0.84 – 2.48) | 0.18 | 1.15 (0.62 – 2.13) | 0.65 | |
| PAM index comorbidities | ||||||
| Conditioning regimen | ||||||
| Nonmyeloablative | 174 (6) | 87 | 1 | 1 | ||
| Non-TBI | 108 (38) | 10 | 0.71 (0.39 – 1.32) | 0.28 | 1.04 (0.52 – 2.08) | 0.92 |
| TBI with ≤ 12 Gy | 64 (22) | 8 | 0.92 (0.46 – 1.85) | 0.82 | 0.93 (0.42 – 2.10) | 0.87 |
| Disease risk | ||||||
| Low | 38 (13) | 37 | 1 | 1 | ||
| Intermediate | 156 (55) | 56 | 1.33 (0.55 – 3.21) | 0.53 | 0.46 (0.17 – 1.20) | 0.11 |
| High | 92 (32) | 24 | 1.57 (0.63 – 3.94) | 0.33 | 0.42 (0.15 – 1.18) | 0.10 |
| Matched related donor | 149 (52) | 7 | 0.39 (0.22 – 0.68) | 0.001 | 0.53 (0.28 – 1.00) | 0.050 |
| Serum creatinine level > 1.2 mg/dL | 5 (2) | 35 | 2.23 (0.54 – 9.14) | 0.27 | 2.23 (0.54 – 9.24) | 0.27 |
| Serum ALT level > 49 U/L | 110 (38) | 39 | 0.79 (0.45 – 1.39) | 0.42 | 0.73 (0.38 – 1.39) | 0.34 |
| CCI comorbidities | ||||||
| Congestive heart failure | 9 (3) | ND | 1.19 (0.29 – 4.87) | 0.81 | 1.19 (0.29 – 4.95) | 0.81 |
| Cerebrovascular disease | 19 (7) | ND | 0.24 (0.03 – 1.77) | 0.16 | 0.50 (0.07 – 3.64) | 0.49 |
| Hepatic disease (only mild in the cohort) | 16 (6) | ND | 2.55 (1.09 – 5.97) | 0.031 | 2.76 (1.08 – 7.06) | 0.033 |
| Solid tumor without metastases | 7 (2) | ND | 1.65 (0.40 – 6.77) | 0.49 | 1.67 (0.40 – 6.88) | 0.48 |
| HCT-CI comorbidities | ||||||
| Cardiac | 17 (6) | 4 | 1.18 (0.43 – 3.28) | 0.75 | 1.28 (0.45 – 3.58) | 0.64 |
| Cerebrovascular disease | 19 (7) | ND | 0.24 (0.03 – 1.77) | 0.16 | 0.50 (0.07 – 3.64) | 0.49 |
| Psychiatric disturbance | 13 (4) | 20 | 1.39 (0.43 – 4.46) | 0.58 | 1.41 (0.44 – 4.56) | 0.57 |
| Hepatic disease | ||||||
| Mild | 91 (32) | 38 | 0.73 (0.39 – 1.35) | 0.31 | 0.77 (0.39 – 1.56) | 0.48 |
| Moderate/severe | 45 (16) | 41 | 0.73 (0.33 – 1.59) | 0.43 | 1.23 (0.50 – 3.02) | 0.65 |
| Infection | 67 (23) | 58 | 1.15 (0.62 – 2.12) | 0.66 | 1.10 (0.54 – 2.24) | 0.80 |
| Heart valve disease | 13 (4) | 12 | 1.33 (0.41 – 4.27) | 0.63 | 1.39 (0.43 – 4.54) | 0.58 |
| Solid tumor | 7 (2) | 0 | 1.65 (0.40 – 6.77) | 0.49 | 1.67 (0.40 – 6.88) | 0.48 |
ND no or insufficient data to compare with